Swedish researchers have developed an experimental diabetes pill that burns fat by revving up muscle metabolism—and early trials suggest it does so without the muscle-wasting and digestive troubles that plague current injected weight loss drugs. The finding, published in Cell by teams at Karolinska Institutet and Stockholm University, points toward a fundamentally different approach to treating type 2 diabetes and obesity: instead of telling your brain you're full, the drug awakens the metabolic machinery inside your muscles themselves.
The distinction matters because popular GLP-1 medications like Ozempic work by suppressing appetite through signals between the gut and brain. They're effective, but they come with trade-offs. Patients often lose muscle along with fat, experience digestive side effects, and must endure regular injections. This new treatment takes the opposite path. By activating important signaling pathways within skeletal muscle, it improved blood sugar regulation and body composition in animal studies while sidestepping appetite suppression, muscle loss, and digestive issues altogether. Better yet, it comes as a tablet.
The researchers engineered the compound around a molecule called a β2 agonist, redesigning it to stimulate muscle tissue without overstimulating the heart—a historic limitation that had kept similar compounds on the shelf for decades. In an initial Phase I trial involving 48 healthy volunteers and 25 people with type 2 diabetes, participants tolerated the treatment well.
"Our results point to a future where we can improve metabolic health without losing muscle mass," says Tore Bengtsson, professor at Stockholm University's Department of Molecular Bioscience and one of the lead researchers. "Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy." That last point is worth sitting with: the pill isn't just about weight loss, but about preserving the tissue most closely linked to how long and how well we live.
Shane C. Wright, an assistant professor at Karolinska Institutet and co-author of the study, frames the breakthrough in practical terms: "This drug represents a completely new type of treatment and has the potential to be of great importance for patients with type 2 diabetes and obesity. Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections."
Because this drug works through an entirely different mechanism than GLP-1 medications, researchers believe it could function both as a standalone treatment and alongside existing therapies—potentially opening doors for combination approaches that tackle metabolic disease from multiple angles at once. Wright notes the compounds are "valuable both as a stand-alone treatment and in combination with GLP-1 drugs."
The research involved scientists from institutions across Scandinavia and Australia, supported by the Swedish Research Council, the Swedish Society for Medical Research, and the Novo Nordisk Foundation. The next phase is a larger Phase II clinical trial led by Atrogi AB, the company developing the drug, which will test whether early promise translates into real-world benefits for people living with type 2 diabetes or obesity. If it does, patients facing metabolic disease may soon have a choice that preserves the very tissue their bodies need most.